Drugs / AMAG-423
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT03008616 Comparator | Apr 2017 → Aug 2020 | severe pre-eclampsia | AMAG Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMAG-423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03008616 ↗ |
| Known as | digoxin immune fab | “AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days” NCT03008616 ↗ |
| Route | Intravenous | “AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days” NCT03008616 ↗ |